vs

Side-by-side financial comparison of BayCom Corp (BCML) and Pulmonx Corp (LUNG). Click either name above to swap in a different company.

BayCom Corp is the larger business by last-quarter revenue ($25.9M vs $20.6M, roughly 1.3× Pulmonx Corp). BayCom Corp runs the higher net margin — 26.5% vs -66.3%, a 92.8% gap on every dollar of revenue. On growth, BayCom Corp posted the faster year-over-year revenue change (9.4% vs -8.7%). Over the past eight quarters, BayCom Corp's revenue compounded faster (2.9% CAGR vs -0.5%).

BayCom Corp is a U.S.-headquartered bank holding company operating through its wholly owned subsidiary Bay Commercial Bank. It primarily serves small and medium-sized enterprises and retail customers across Northern California, offering commercial lending, deposit products, personal banking services, and localized wealth management solutions.

Pulmonx Corp is a global medical tech firm focused on interventional pulmonology solutions. It develops minimally invasive endobronchial valves to treat severe COPD and emphysema, with products sold across North America, Europe, and Asia-Pacific for patients with advanced lung conditions.

BCML vs LUNG — Head-to-Head

Bigger by revenue
BCML
BCML
1.3× larger
BCML
$25.9M
$20.6M
LUNG
Growing faster (revenue YoY)
BCML
BCML
+18.1% gap
BCML
9.4%
-8.7%
LUNG
Higher net margin
BCML
BCML
92.8% more per $
BCML
26.5%
-66.3%
LUNG
Faster 2-yr revenue CAGR
BCML
BCML
Annualised
BCML
2.9%
-0.5%
LUNG

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
BCML
BCML
LUNG
LUNG
Revenue
$25.9M
$20.6M
Net Profit
$6.9M
$-13.7M
Gross Margin
77.9%
Operating Margin
36.6%
-40.9%
Net Margin
26.5%
-66.3%
Revenue YoY
9.4%
-8.7%
Net Profit YoY
12.1%
5.5%
EPS (diluted)
$0.63
$-0.33

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BCML
BCML
LUNG
LUNG
Q1 26
$20.6M
Q4 25
$25.9M
$22.6M
Q3 25
$25.7M
$21.5M
Q2 25
$24.7M
$23.9M
Q1 25
$24.3M
$22.5M
Q4 24
$23.7M
$23.8M
Q3 24
$25.6M
$20.4M
Q2 24
$23.8M
$20.8M
Net Profit
BCML
BCML
LUNG
LUNG
Q1 26
$-13.7M
Q4 25
$6.9M
$-10.4M
Q3 25
$5.0M
$-14.0M
Q2 25
$6.4M
$-15.2M
Q1 25
$5.7M
$-14.4M
Q4 24
$6.1M
$-13.2M
Q3 24
$6.0M
$-14.1M
Q2 24
$5.6M
$-15.3M
Gross Margin
BCML
BCML
LUNG
LUNG
Q1 26
77.9%
Q4 25
77.6%
Q3 25
74.7%
Q2 25
72.1%
Q1 25
72.5%
Q4 24
74.0%
Q3 24
73.7%
Q2 24
73.7%
Operating Margin
BCML
BCML
LUNG
LUNG
Q1 26
-40.9%
Q4 25
36.6%
-43.8%
Q3 25
26.3%
-66.9%
Q2 25
35.3%
-62.0%
Q1 25
31.6%
-64.6%
Q4 24
34.2%
-56.5%
Q3 24
32.4%
-69.3%
Q2 24
31.9%
-75.2%
Net Margin
BCML
BCML
LUNG
LUNG
Q1 26
-66.3%
Q4 25
26.5%
-46.1%
Q3 25
19.5%
-64.9%
Q2 25
25.8%
-63.6%
Q1 25
23.4%
-64.1%
Q4 24
25.9%
-55.4%
Q3 24
23.5%
-69.4%
Q2 24
23.6%
-73.7%
EPS (diluted)
BCML
BCML
LUNG
LUNG
Q1 26
$-0.33
Q4 25
$0.63
$-0.25
Q3 25
$0.46
$-0.34
Q2 25
$0.58
$-0.38
Q1 25
$0.51
$-0.36
Q4 24
$0.55
$-0.33
Q3 24
$0.54
$-0.36
Q2 24
$0.50
$-0.39

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BCML
BCML
LUNG
LUNG
Cash + ST InvestmentsLiquidity on hand
$61.6M
Total DebtLower is stronger
$37.3M
Stockholders' EquityBook value
$338.6M
$45.8M
Total Assets
$2.6B
$120.0M
Debt / EquityLower = less leverage
0.82×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BCML
BCML
LUNG
LUNG
Q1 26
$61.6M
Q4 25
$69.8M
Q3 25
$76.5M
Q2 25
$75.5M
Q1 25
$74.6M
Q4 24
$70.9M
Q3 24
$63.3M
Q2 24
$63.5M
Total Debt
BCML
BCML
LUNG
LUNG
Q1 26
$37.3M
Q4 25
$37.1M
Q3 25
$37.1M
Q2 25
$37.1M
Q1 25
$37.2M
Q4 24
$37.2M
Q3 24
$37.2M
Q2 24
$37.2M
Stockholders' Equity
BCML
BCML
LUNG
LUNG
Q1 26
$45.8M
Q4 25
$338.6M
$54.1M
Q3 25
$334.3M
$60.0M
Q2 25
$330.6M
$69.1M
Q1 25
$329.3M
$77.7M
Q4 24
$324.4M
$85.8M
Q3 24
$321.7M
$93.9M
Q2 24
$315.3M
$101.2M
Total Assets
BCML
BCML
LUNG
LUNG
Q1 26
$120.0M
Q4 25
$2.6B
$129.3M
Q3 25
$2.6B
$138.3M
Q2 25
$2.6B
$147.2M
Q1 25
$2.6B
$150.7M
Q4 24
$2.7B
$162.8M
Q3 24
$2.6B
$167.4M
Q2 24
$2.6B
$172.6M
Debt / Equity
BCML
BCML
LUNG
LUNG
Q1 26
0.82×
Q4 25
0.69×
Q3 25
0.62×
Q2 25
0.54×
Q1 25
0.48×
Q4 24
0.43×
Q3 24
0.40×
Q2 24
0.37×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BCML
BCML
LUNG
LUNG
Operating Cash FlowLast quarter
$31.8M
Free Cash FlowOCF − Capex
$30.1M
FCF MarginFCF / Revenue
116.2%
Capex IntensityCapex / Revenue
6.7%
Cash ConversionOCF / Net Profit
4.64×
TTM Free Cash FlowTrailing 4 quarters
$51.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BCML
BCML
LUNG
LUNG
Q1 26
Q4 25
$31.8M
$-7.1M
Q3 25
$7.3M
$-8.2M
Q2 25
$6.4M
$-3.9M
Q1 25
$9.3M
$-13.2M
Q4 24
$30.4M
$-6.7M
Q3 24
$9.6M
$-7.2M
Q2 24
$7.7M
$-5.8M
Free Cash Flow
BCML
BCML
LUNG
LUNG
Q1 26
Q4 25
$30.1M
$-7.1M
Q3 25
$6.2M
$-8.3M
Q2 25
$5.6M
$-4.0M
Q1 25
$9.1M
$-13.5M
Q4 24
$28.7M
$-6.8M
Q3 24
$9.4M
$-7.7M
Q2 24
$7.4M
$-6.2M
FCF Margin
BCML
BCML
LUNG
LUNG
Q1 26
Q4 25
116.2%
-31.4%
Q3 25
24.3%
-38.4%
Q2 25
22.8%
-16.6%
Q1 25
37.6%
-60.0%
Q4 24
121.1%
-28.8%
Q3 24
36.6%
-37.6%
Q2 24
31.2%
-30.0%
Capex Intensity
BCML
BCML
LUNG
LUNG
Q1 26
Q4 25
6.7%
0.1%
Q3 25
4.3%
0.4%
Q2 25
3.0%
0.2%
Q1 25
0.6%
1.3%
Q4 24
7.2%
0.5%
Q3 24
1.0%
2.0%
Q2 24
1.0%
2.3%
Cash Conversion
BCML
BCML
LUNG
LUNG
Q1 26
Q4 25
4.64×
Q3 25
1.47×
Q2 25
1.00×
Q1 25
1.63×
Q4 24
4.96×
Q3 24
1.60×
Q2 24
1.37×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons